en
ua
en
EGW-NewsCS:GOAll newsPeppzor is the fifth EYEBALLERS player
Peppzor is the fifth EYEBALLERS player
1671
0
0

Peppzor is the fifth EYEBALLERS player

The Swedish esports organization EYEBALLERS has completed its CS:GO roster by signing a contract with Peppzor. The 20-year-old Swedish player is called to replace Svedjehed, who left the watch team earlier.

We are very happy to announce that Peppzor has joined EYEBALLERS! His talent and dedication will be our biggest asset as we strive to be successful in 2023! Welcome to the team, Peppzor!

Peppzor has joined fnatic for the last two seasons. For a long time, the 20-year-old Swede sat without playing practice, but in the summer he got into the Fnatic Rising roster. Here, the young esportsman became the winner of WePlay Academy League Season 5, and also got into the TOP-3 at the end of WePlay Academy League Season 1 and ESL Challenger League Season 42 Relegation: Europe.

Moreover, Peppzor was repeatedly involved in the fnatic main team, with which he managed to win Elisa Masters Espoo 2022, as well as play at ESL Pro League Season 15 and PGL Major Antwerp 2022: European RMR A. However, in early December, the young Swede left organization as a free agent.

Farmskins

Sign up now and get 2 FREE CASES + 5$ Bonus

Farmskins
CS:GO
Claim bonus
CSGOLuck

3 Free Cases + 100% up to 100 Coins on First Deposit

CSGOLuck
CS:GO
Claim bonus
Chicken.gg

Free gems, plus daily, weekly, & monthly boosts!

Chicken.gg
CS:GO
Claim bonus

A little earlier, the EYEBALLERS team officially said goodbye to Svedjehed.

The next championship for the Swedish team is ESL Challenger League Season 44: Europe. However, there is a chance to see the team in action a little earlier, at one of the CCT series tournaments.

Updated EYEBALLERS CS:GO roster:

  • JW
  • flusha
  • Sapec
  • SHINE
  • slap (coach)
Leave comment
Did you like the article?
0
0

More about teams:

EYEBALLERSEYEBALLERSEGW

More about players:

PeppzorPeppzorEGW

Comments

BRING TO TOP
FREE SUBSCRIPTION ON EXCLUSIVE CONTENT
Receive a selection of the most important and up-to-date news in the industry.
*
*Only important news, no spam.
SUBSCRIBE
LATER
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic.
Customize
OK